SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer

Table 1

Clinicopathological characteristics of the patient cohort (n  = 137).

Variables	Patients, % (n)
Expression of SFRP4
High	70.07 (96)
Low	29.93 (41)
Age (year)
>60	53.28 (73)
≤55	46.72 (64)
Sex
Female	29.20 (40)
Male	70.80 (97)
Smoking
Yes	36.50 (50)
No	63.50 (87)
Drinking
Yes	24.09 (33)
No	75.91 (104)
Weight loss
Yes	38.69 (53)
No	60.58 (83)
Unknown	0.73 (1)
Family history
Yes	14.60 (20)
No	85.40 (117)
Tumor location
Proximal gastric cancer	31.39 (43)
Distal gastric cancer	62.04 (85)
Total stomach	6.57 (9)
Borrmann type
I/II	56.20 (77)
III/IV	42.34 (58)
Unknown	1.46 (2)
Lauren type
Intestinal	50.36 (69)
Diffuse	36.50 (50)
Mixed	13.14 (18)
Grade of differentiation
Poor/well	44.53 (61)
Moderate/moderate-poor	51.82 (71)
Unknown	3.65 (5)
Pathological type
Signet ring cell carcinoma/mucinous adenocarcinoma	10.22 (14)
Adenocarcinoma	89.78 (123)
Tumor size (cm)
≥5 cm	64.96 (89)
<5 cm	32.85 (45)
Unknown	2.19 (3)
T stage
T1/T2	5.11 (7)
T3/T4	94.89 (130)
N stage
N0	7.30 (10)
N1/N2/N3	92.70 (127)
M stage
M0	90.51 (124)
M1	9.49 (13)
TNM stage
I	0.73 (1)
II	12.41 (17)
III	77.37 (106)
IV	9.49 (13)
Nerve invasion
Positive	75.18 (103)
Negative	24.82 (34)
Vascular invasion
Positive	58.39 (80)
Negative	41.61 (57)
AFP (ng/ml)
>8.1	5.84 (8)
≤8.1	92.70 (127)
Unknown	1.46 (2)
CA19-9 (U/ml)
>37	33.58 (46)
≤37	64.69 (90)
Unknown	0.73 (1)
PD-L1
Positive	35.04 (48)
Negative	64.96 (89)
CD3
High	51.09 (70)
Low	48.91 (67)
CD4
High	51.82 (71)
Low	48.18 (66)
CD8
High	49.64 (68)
Low	50.36 (69)